GLP Fat Loss — Advanced Peptide Stack
Triple-agonist (GLP-1 + GIP + glucagon) — typically more potent fat loss + energy expenditure than semaglutide or tirzepatide. Higher response variance; titrate carefully.
What's in this stack
Retatrutide is a synthetic peptide that simultaneously activates the GLP‑1, GIP, and glucagon receptors, and is being investigated for its potential to support weight management and metabolic health.
Who this stack is for
Experienced users seeking more aggressive fat loss and metabolic effect than semaglutide or tirzepatide typically deliver, who can manage a higher-variance response.
How to run it
Retatrutide is injected once weekly, carefully titrated. As a triple agonist it is potent — conservative dose escalation and close attention to GI tolerance and hydration matter more here than with single-agonist GLPs.
What to expect
Often stronger appetite suppression and energy-expenditure effects than earlier GLPs, with a wider individual response range. The 12-week block should be run with the same nutrition + training scaffolding as the starter protocol.
Frequently asked questions
What makes retatrutide different from semaglutide?
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon receptors). The glucagon component adds an energy-expenditure effect, which is why many report stronger fat loss — with more individual variability.
Is retatrutide stronger than tirzepatide?
In many users, yes — the added glucagon agonism can drive greater fat loss and metabolic effect. It also means careful titration and tolerance management are more important.
Who should not start with retatrutide?
People new to GLP agonists are usually better served starting with semaglutide to establish tolerance. Retatrutide suits those who understand their response to this drug class.
Related stacks
This stack is an educational starting point based on common practitioner combinations. Doses are typical mid-range references — adjust to your own sensitivity and goals, and always consult a qualified practitioner before acting on any protocol. Aevum does not sell, source, or administer any component.